Aopia Bioscience is a cutting-edge biotechnology company (founded in 2019 and based in North America) specializing in automated isolation and purification of total extracellular vesicles (TEVs) from conditioned culture media or large volumes of biofluids. Their flagship NanoEX™ platform, powered by breakthrough hydrophilic Asymmetric Nanopore Membrane (ANM) and VanoFlow® cassette technologies, delivers fully enclosed processing with exceptional yield and purity, capable of processing up to 2L EV feed volume in about four hours while removing over 99% of free proteins. Designed for everything from R&D, pre-clinical use to large-scale therapeutic production, NanoEX™ offers researchers and manufacturers a scalable, affordable solution optimized for high purity TEV isolation and enrichment.
